Daniel Lavanchy

13.4k total citations · 4 hit papers
66 papers, 7.1k citations indexed

About

Daniel Lavanchy is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Daniel Lavanchy has authored 66 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Epidemiology, 44 papers in Hepatology and 10 papers in Infectious Diseases. Recurrent topics in Daniel Lavanchy's work include Hepatitis C virus research (41 papers), Hepatitis B Virus Studies (34 papers) and Liver Disease Diagnosis and Treatment (26 papers). Daniel Lavanchy is often cited by papers focused on Hepatitis C virus research (41 papers), Hepatitis B Virus Studies (34 papers) and Liver Disease Diagnosis and Treatment (26 papers). Daniel Lavanchy collaborates with scholars based in Switzerland, United States and Egypt. Daniel Lavanchy's co-authors include Christina Frank, Ismail Sallam, G. Thomas Strickland, Mostafa K. Mohamed, Ray R. Arthur, Laurence S. Magder, Wagida A. Anwar, Mary Ellen Kitler, P. C. Frei and Pierre Van Damme and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Daniel Lavanchy

65 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

2004 2.1k citations Daniel Lavanchy Journal of Viral Hepatitis profile →
The global burden of hepatitis C

2009 1.1k citations Daniel Lavanchy Liver International profile →
Evolving epidemiology of hepatitis C virus

2010 1.0k citations Daniel Lavanchy Clinical Microbiology and Infection profile →
The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

2000 807 citations Daniel Lavanchy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Lavanchy Switzerland	27	5.8k	5.7k	799	504	416	66	7.1k
M J Alter United States	25	4.6k 0.8×	5.1k 0.9×	796 1.0×	420 0.8×	225 0.5×	55	6.1k
Daniel Shouval Israel	48	6.1k 1.1×	5.9k 1.0×	1.7k 2.1×	772 1.5×	829 2.0×	225	8.8k
Alfred M. Prince United States	38	4.0k 0.7×	3.1k 0.5×	1.1k 1.4×	695 1.4×	698 1.7×	125	6.1k
Ola Weiland Sweden	47	7.2k 1.2×	7.6k 1.3×	1.5k 1.9×	409 0.8×	611 1.5×	254	9.2k
Colin W. Shepard United States	25	3.4k 0.6×	2.6k 0.5×	1.2k 1.5×	361 0.7×	246 0.6×	58	4.5k
C. Trépo France	46	9.1k 1.6×	9.4k 1.7×	1.2k 1.5×	669 1.3×	737 1.8×	200	11.2k
R. Palmer Beasley United States	29	5.9k 1.0×	4.8k 0.9×	918 1.1×	703 1.4×	510 1.2×	70	7.8k
Kenneth E. Sherman United States	44	5.8k 1.0×	6.7k 1.2×	2.2k 2.7×	562 1.1×	452 1.1×	250	8.7k
Gamal Esmat Egypt	39	3.3k 0.6×	3.4k 0.6×	492 0.6×	696 1.4×	342 0.8×	288	5.6k
Myron J. Tong United States	60	10.3k 1.8×	10.7k 1.9×	1.1k 1.4×	955 1.9×	619 1.5×	262	14.1k

Countries citing papers authored by Daniel Lavanchy

Since Specialization

Citations

This map shows the geographic impact of Daniel Lavanchy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Lavanchy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Lavanchy more than expected).

Fields of papers citing papers by Daniel Lavanchy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Lavanchy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Lavanchy. The network helps show where Daniel Lavanchy may publish in the future.

Co-authorship network of co-authors of Daniel Lavanchy

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Lavanchy. A scholar is included among the top collaborators of Daniel Lavanchy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Lavanchy. Daniel Lavanchy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Müllhaupt, Beat, Philip Bruggmann, Florian Bihl, et al.. (2018). Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. PLoS ONE. 13(12). e0209374–e0209374. 9 indexed citations

Pfeil, Alena M., Oliver Reich, S. Cure, et al.. (2015). Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C. PLoS ONE. 10(5). e0126984–e0126984. 34 indexed citations

Müllhaupt, Beat, Philip Bruggmann, Florian Bihl, et al.. (2015). Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS ONE. 10(6). e0125214–e0125214. 22 indexed citations

Fretz, R., Francesco Negro, Philip Bruggmann, et al.. (2013). Hepatitis B and C in Switzerland – healthcare provider initiated testing for chronic hepatitis B and C infection. Swiss Medical Weekly. 143(1920). w13793–w13793. 26 indexed citations

Mahboobi, Nima, et al.. (2010). Hepatitis B virus infection in dentistry: a forgotten topic. Journal of Viral Hepatitis. 17(5). 307–316. 73 indexed citations

Lavanchy, Daniel. (2010). Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection. 17(2). 107–115. 1019 indexed citations breakdown →

Lavanchy, Daniel. (2009). The global burden of hepatitis C. Liver International. 29(s1). 74–81. 1050 indexed citations breakdown →

Lavanchy, Daniel. (2005). Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. Journal of Clinical Virology. 34. S1–S3. 373 indexed citations

Lavanchy, Daniel. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis. 11(2). 97–107. 2102 indexed citations breakdown →

10.

Kew, M C, Guido François, Daniel Lavanchy, et al.. (2004). Prevention of hepatitis C virus infection*. Journal of Viral Hepatitis. 11(3). 198–205. 31 indexed citations

11.

Lavanchy, Daniel, et al.. (2001). Recommendations for the use of inactivated influenza vaccines and other preventive measures. Vaccine. 19(15-16). 1849–1853. 11 indexed citations

12.

Gust, Ian D., Alan Hampson, & Daniel Lavanchy. (2001). Planning for the next pandemic of influenza. Reviews in Medical Virology. 11(1). 59–70. 30 indexed citations

13.

Woodhead, Mark, Daniel Lavanchy, Stephen S. Johnston, Peter M. Colman, & D Fleming. (2000). NEURAMINIDASE INHIBITORS: PROGRESS IN THE MANAGEMENT OF INFLUENZA. International Journal of Clinical Practice. 54(9). 604–610. 1 indexed citations

14.

Lavanchy, Daniel. (1999). Hepatitis C: public health strategies. Journal of Hepatology. 31. 146–151. 33 indexed citations

15.

Lavanchy, Daniel. (1999). The importance of global surveillance of influenza. Vaccine. 17. S24–S25. 16 indexed citations

16.

Reichen, Jürg, Leonardo Bianchi, Hugo Bühler, et al.. (1996). Fixed versus titrated interferon-α2B in chronic hepatitis C. A randomized controlled multicenter trial. Journal of Hepatology. 25(3). 275–282. 15 indexed citations

17.

Bart, Pierre‐Alexandre, P Jacquier, Patrick Zuber, Daniel Lavanchy, & P. C. Frei. (1996). Seroprevalence of HBV (anti‐HBc, HBsAg and anti‐HBs) and HDV infections among 9006 women at delivery*. Liver International. 16(2). 110–116. 28 indexed citations

18.

Lavanchy, Daniel, Jochen Steinmann, Andreas Moritz, & P. C. Frei. (1996). Evaluation of a new automated third-generation anti-HCV enzyme immunoassay. Journal of Clinical Laboratory Analysis. 10(5). 269–276. 8 indexed citations

19.

Reichen, Jürg, et al.. (1994). Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B. Journal of Hepatology. 20(2). 168–174. 29 indexed citations

20.

Lavanchy, Daniel, et al.. (1993). Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. Vaccine. 11(10). 1027–1032. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact